Patents by Inventor Michael Bech Jensen
Michael Bech Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130017184Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.Type: ApplicationFiled: September 10, 2012Publication date: January 17, 2013Applicant: NOVO NORDISK HEALTHCARE A/GInventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
-
Patent number: 8318904Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilizing agent (iii) comprising a —C(?N—Z1—R1)—NH—Z2—R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.Type: GrantFiled: September 16, 2011Date of Patent: November 27, 2012Assignee: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
-
Patent number: 8299029Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.Type: GrantFiled: September 25, 2006Date of Patent: October 30, 2012Assignee: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
-
Publication number: 20120004176Abstract: A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM.Type: ApplicationFiled: September 14, 2011Publication date: January 5, 2012Applicant: Novo Nordisk A/SInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20120003206Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(?N—Z1—R1)—NH—Z2—R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.Type: ApplicationFiled: September 16, 2011Publication date: January 5, 2012Applicant: Novo Nordisk HealthCare A/GInventors: Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
-
Patent number: 8026214Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(?N—Z1—R1)—NH—Z2—R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.Type: GrantFiled: November 12, 2009Date of Patent: September 27, 2011Assignee: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
-
Patent number: 8022031Abstract: A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM.Type: GrantFiled: June 24, 2003Date of Patent: September 20, 2011Assignee: Novo Nordisk Health Care A/GInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20110104142Abstract: The invention relates to a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i) functionalised with one or more polyethylene glycol (PEG) moieties, said PEG moieties having a molecular weight of at least 300 Da; a buffering agent (ii) suitable for keeping pH in the range of from about 5.0 to about 9.0; and at least one aromatic preservative (iii) in a concentration of at least 0.1 mg/mL.Type: ApplicationFiled: May 22, 2009Publication date: May 5, 2011Applicant: Novo Nordisk Health Care AGInventors: Christian Rischel, Anders Dybdal, Michael Bech Jensen
-
Publication number: 20100294677Abstract: The present invention relates to pharmaceutical compositions comprising at least 10 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 5.0 to about 9.0; at least one aromatic preservative (iii) in a concentration of at least 0.1 mg/mL; and at least one antioxidant (iv) in a concentration of at least 0.1 mg/mL; the composition optionally comprising further components, with the proviso that none of such further components are Factor VII polypeptide stabilizing agents selected from (a) metal-containing agents, wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc; and (b) stabilising agent comprising a —C(?N—Z1-R1)-NH—Z2-R2 motif.Type: ApplicationFiled: April 30, 2008Publication date: November 25, 2010Applicant: Novo Nordisk Health Care AGInventors: Christian Rischel, Michael Bech Jensen, Anders Dybdal Nielsen
-
Patent number: 7790852Abstract: The invention concerns a liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 9.0; (iii) an agent selected from the group consisting of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is less than 15 mM; and (iv) An ionic strength modifying agent; wherein the ionic strength of the composition is at least 200 mM.Type: GrantFiled: May 20, 2008Date of Patent: September 7, 2010Assignee: Novo Nordisk Health Care A/GInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20100166730Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and/or physical degradation.Type: ApplicationFiled: August 6, 2009Publication date: July 1, 2010Applicant: Novo Nordisk Health Care A/GInventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt, Kristen Kramer Jacobsen
-
Patent number: 7732405Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilizing agent (iii) comprising a —C(?N-Z1-R1)—NH-Z2-R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.Type: GrantFiled: February 14, 2006Date of Patent: June 8, 2010Assignee: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
-
Publication number: 20100056453Abstract: The present invention is directed to liquid, aqueous pharmaceutical compositions stabilised against chemical and/or physical degradation containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising at least 0.01 mg/mL of a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; and at least one stabilising agent (iii) comprising a —C(?N—Z1—R1)—NH—Z2—R2 motif, e.g. benzamidine compounds and guanidine compounds such as arginine.Type: ApplicationFiled: November 12, 2009Publication date: March 4, 2010Applicant: Novo Nordisk HealthCare A/GInventors: Michael Bech Jensen, Anders Klarskov Petersen, Andrew Neil Bowler
-
Publication number: 20090181895Abstract: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.Type: ApplicationFiled: March 19, 2009Publication date: July 16, 2009Applicant: Novo Nordisk Health Care AGInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20090111751Abstract: The invention relates to a method for removing a protein inhibitor from a liquid pharmaceutical preparation, said method comprising the steps of: (a) providing a sealed container comprising an initial liquid pharmaceutical preparation comprising (i) a protein belonging to the group of serine proteases/Vitamin K-dependent proteins and (ii) a non-metallic inhibitor for said protein; (b) contacting said pharmaceutical preparation with a solid phase polymeric material capable of retaining at least a substantial portion of said inhibitor; and (c) separating said liquid pharmaceutical preparation from said solid phase polymeric material so as to obtain a resulting liquid pharmaceutical preparation having a reduced concentration of said inhibitor compared to the initial liquid pharmaceutical preparation.Type: ApplicationFiled: February 22, 2007Publication date: April 30, 2009Applicant: Novo Nordisk Health Care AGInventors: Michael Bech Jensen, Ulrik Nosted, Karen Pilgaard
-
Publication number: 20080227715Abstract: The invention concerns a liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 9.0; (iii) an agent selected from the group consisting of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is less than 15 mM; and (iv) An ionic strength modifying agent; wherein the ionic strength of the composition is at least 200 mM.Type: ApplicationFiled: May 20, 2008Publication date: September 18, 2008Applicant: Novo Nordisk HealthCare A/GInventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20040248793Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.Type: ApplicationFiled: June 30, 2003Publication date: December 9, 2004Inventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
-
Publication number: 20040043933Abstract: The invention provides a liquid, aqueous composition, comprising (i) a modified factor VII polypeptide; (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an antioxidant; and (iv) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof.Type: ApplicationFiled: June 23, 2003Publication date: March 4, 2004Inventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
-
Publication number: 20040037893Abstract: A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM.Type: ApplicationFiled: June 24, 2003Publication date: February 26, 2004Inventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt